Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

被引：8

作者：

Chawla, S. P.

Blay, J.

Ray-Coquard, I. L.

Le Cesne, A.

Staddon, A. P.

Milhem, M. M.

Penel, N.

Riedel, R. F.

Nguyen, B. Bui

Cranmer, L. D.

Reichardt, P.

Bompas, E.

Song, Y.

Lee, R.

Eid, J. E.

Loewy, J.

Haluska, F. G.

Dodion, P. F.

Demetri, G. D.

机构：

[1] Sarcoma Oncol Ctr, Santa Monica, CA USA

[2] Ctr Leon Berard, F-69373 Lyon, France

[3] Inst Gustave Roussy, Villejuif, France

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] Univ Iowa, Iowa City, IA USA

[6] Ctr Oscar Lambret, F-59020 Lille, France

[7] Duke Univ, Med Ctr, Durham, NC USA

[8] Inst Bergonie, Bordeaux, France

[9] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA

[10] HELIOS Klinikum Bad Saarow, Sarcoma Ctr Berlin Brandenburg, Bad Saarow Pieskow, Germany

[11] Ctr Rene Gauducheau, F-44035 Nantes, France

[12] Merck Res Labs, N Wales, PA USA

[13] Merck Sharp & Dohme Ltd, N Wales, PA USA

[14] ARIAD Pharmaceut, Cambridge, MA USA

[15] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.10005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10005

引用

页数：1